Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Leukemia

Breaking Barriers: An Egyptian Immigrant's Journey with ALL

Kristie L. Kahl

In this episode of the “CURE Talks Cancer” podcast, we spoke with Bishoy Tadros, who went on to break barriers after he was diagnosed with acute lymphoblastic leukemia at the age of 3 and immigrated to the United States from Egypt to receive treatment.

Fixed-Duration Regimen More Cost-Effective Than Treat-Until-Progression Therapies in CLL

Beth Fand Incollingo

The novel drug pairing of Venclexta and Gazyva, used for a fixed 12 months, is cost-effective compared with regimens that must be taken until disease progresses, a study finds.

Mutations in Donor Stem Cells Could Harm the Health of Patients with Cancer, Study Finds

Katie Kosko

Research findings show that rare mutations from donor stem cells can be passed onto patients who receive them, potentially causing health concerns.

Choosing the Best Therapy for Patients with Chronic Lymphocytic Leukemia

Katie Kosko

With many targeted treatment options for patients with CLL to use upfront, the question arises as to which one is best for the individual.

Limiting Treatment Duration Improves Cost Effectiveness in CLL

Dr. Matthew Davids

Researchers are exploring ways to limit the duration of treatment in chronic lymphocytic leukemia in order to reduce costs.

Clinical Trial Participants May Fare Better Than Medicare Beneficiaries Treated with Zydelig

Kristie L. Kahl

Those with follicular lymphoma and chronic lymphocytic leukemia who were treated with Zydelig in the clinical setting experienced less favorable outcomes, compared with those treated in a clinical trial.

A Look Back at the Top 10 CURE Stories of 2019

Jessica Skarzynski

As 2019 comes to a close, take a read through CURE®’s top stories of the year.

MDM2 Inhibitor Shows Promise For Patients With AML

Naval Daver, MD

New findings show that a wider study is needed for MDM2 inhibitors in treating patients with AML.

Don't Ignore Your Wake-Up Call

Rachelle Berfond

When one woman experienced symptoms of chronic lymphocytic leukemia, people blamed her nerves and told her to rest. Instead, she listened to her body.

Investigational Oral Chemotherapy Boosts Survival in Older Patients with AML

Tom Castles

Patients aged 55 and over remained in remission after receiving CC-486, according to phase 3 study findings.

Leukemia

Sign In